Business
Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
Late-breaking poster presentation at ASN’s Kidney Week 2023 - - -Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13, 2023 (GLOBE
About this update from Mineralys Therapeutics, Inc.
[{"type":"text","content":"Late-breaking poster presentation at ASN’s Kidney Week 2023 - - -Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced upcoming poster presentations at two scientific conferences being held in November 2023, including: ASN’s Kidney Week 2023 – Late-Breaking Poster Details: David Rodman, Chief Medical Officer of Mineralys, will present a late-breaking poster highlighting lorundrostat’s treatment effect in an endotype of hypertension at the American Society of Nephrology’s (ASN) Kidney Week 2023, which is taking place November 2 - 5, 2023, in Philadelphia, PA. Poster details are below: Poster Title:Identification of a hypertensive endotype with a median treatment effect of -32mmHg in response to the novel aldosterone synthase inhibitor lorundrostatPresenter:Dr. David Rodman, Chief Medical Officer of MineralysPoster Number:TH-PO1121Session Title:Late-Breaking PostersSession Date/Time:Thursday, November 2nd from 10:00 a.m. to 12:00 p.m. ETSession Location:Pennsylvania Convention Center, Exhibit Hall AHA Scientific Sessions 2023 – Poster Details: David Rodman, Chief Medical Officer of Mineralys, will present a poster showing lorundrostat as a potential treatment for obesity-related, aldosterone-dependent hypertension at the American Heart Association (AHA) Scientific Sessions 2023, which is being held from November 10 – 13, 2023, in Philadelphia, PA. Poster details are below: Poster Title:Lorundrostat for Treatment of Obesity-Related, Aldosterone-Dependent Hypertension - An Endotype-Specific, Targeted Approach to the Treatment of Uncontrolled HypertensionPresenter: Dr. David Rodman, Chief Medical Officer of MineralysPoster Number:4121Session Title:Outcomes and Mechanisms of Treatment Approaches for HypertensionSession Date/Time:Saturday, November 11th at 11:30 a.m. – 12:45 p.m. ETSession Location: Pennsylvania Convention Center, Zone 4, Science and Technology Hall, Level 2 About HypertensionHaving sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of dea...